Historical analysis of pharmacoeconomic terms

  • Dominik GregaEmail author
  • Jozef Kolář


Pharmacoeconomy is a young interdisciplinary science at the intersection of pharmacy, medicine and economics, focusing on the social aspects and implications of different types of pharmacotherapy. Tools used by pharmacoeconomists around the world are unified (Cost of Illness Analysis, Cost-Minimization Analysis, Cost-Effectiveness Analysis, Cost-Utility Analysis, Cost–Benefit Analysis, Budget Impact Analysis). The aim of this work was to analyse bibliometric publications containing basic concepts of pharmacoeconomics and, on the basis thereof, to determine when these terms came into use in the medical literature. Search for publications containing the terms of pharmacoeconomics and methods listed above in English as descriptors. Four selected source databases were used for the analysis: Scopus, Web of Science, Science Direct and PubMed. In all cases, the number of publications is different and we cannot rely on the number of source media in individual databases. All parts of the research indicate an increase in publications containing selected terms in the late 1970s and early 1980s. The results provide an overview of how tools used in pharmacoeconomics are developing. As regards the comparison of our source databases, in all cases it is approximately the same period when the number of publications started to increase.


Budget impact Cost–benefit Cost-effectiveness Cost-of-illness Cost-minimization Cost-utility Pharmacoeconomics Publications 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Bootman, J. L., McGhan, W. F., & Schondelmeyer, S. W. (1982). Application of cost-benefit and cost-effectiveness analysis to clinical practice. Drug lntelligence and Clinical Pharmacy. 16(3), 235–243.CrossRefGoogle Scholar
  2. Bootman, J. L., McGhan, W. F., & Townsend, R. J. (2006). Pharmacoeconomics: Historical perspective. Annals of Pharmacotherapy, 40(3), 518–519. Scholar
  3. Bootman, J. L., Townsend, R. J., & McGhan, W. F. (1991). Principles of pharmacoeconomics (1st ed.). Cincinnati, OH: Harvey Whitney Books Co.Google Scholar
  4. Bootman, J. L., Wertheimer, A. I., Zaske, D., & Rowland, C. (1979). Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: A cost-benefit analysis. Journal of Pharmaceutical Sciences, 68(3), 267–272. Scholar
  5. Doležal T. a kol (2007) Základy farmakoekonomiky pro lékaře, lékárniky a další pracovníky ve zdravotnictví (Fundamentals of pharmacoeconomics for doctors, pharmacists and other healthcare workers), 1st ed. Praha: ČFES.Google Scholar
  6. Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddard, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes (4th ed.). Oxford: Oxford University Press.Google Scholar
  7. Elixhauser, A., Halpern, M., Schmier, J., & Luce, B. R. (1998). Health care CBA and CEA from 1991 to 1996: An updated bibliography. Medical Care, 36(5), MS1–MS9.Google Scholar
  8. Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (1996). Cost-effectiveness in health and medicine (pp. 25–54). USA: Oxford University Press.Google Scholar
  9. Jakovljevic, M., & Ogura, S. (2016). Health economics at the crossroads of centuries—From the past to the future. Frontiers in Public Health. Scholar
  10. Jakovljevic, M., & Pejcic, A. V. (2017). Growth of global publishing output of health economics in the twenty-first century: A bibliographic insight. Frontiers in Public Health. Scholar
  11. Jakovljevic, M., Verhaeghe, N., & Souliotis, K. (2018). Editorial: Challenges of pharmacoeconomics in global health arena. Frontiers in Public Health. Scholar
  12. Mauskopf, J. A. (2001). Why study pharmacoeconomics? Expert Review of Pharmacoeconomics & Outcomes Research, 1(1), 1–3. Scholar
  13. McGhan, W. F., Rowland, C. R., & Bootman, J. L. (1978). Cost-benefit and cost-effectiveness: Methodologies for evaluating innovative pharmaceutical services. American Journal of Hospital Pharmacy., 35(2), 133–140.Google Scholar
  14. Nas, T. F. (2016). Cost-benefit analysis: Theory and application (2nd ed.). London: Lexington Books.Google Scholar
  15. Sullivan, S. D., Mauskopf, J. A., Augustovski, F., Caro, J. J., Lee, K. M., Minchin, M., et al. (2014). Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value in Health, 17(1), 5–14.CrossRefGoogle Scholar
  16. Tarricone, R. (2006). Cost-of-illness analysis: What room in health economics? Health Policy, 77(1), 51–63. Scholar
  17. Torrance, G. W., & Feeny, D. (1989). Utilities and quality-adjusted life years. International Journal of Technology Assessment in Health Care, 5(4), 559–575.CrossRefGoogle Scholar
  18. Townsend, R. J. (1987). Postmarketing drug research and development. Drug lntelligence and Clinical Pharmacy, 21(1 Pt 2), 134–136.CrossRefGoogle Scholar
  19. Trueman, P., Drummond, M., & Hutton, J. (2001). Developing guidance for budget impact analysis. Pharmacoeconomics, 19(6), 609–621. Scholar
  20. von Neumann, J., & Morgenstern, O. (1944). Theory of games and economic behavior. Princeton, NJ: Princeton University Press.zbMATHGoogle Scholar
  21. Wagstaff, A., & Culyer, A. J. (2012). Four decades of health economics through a bibliometric lens. Journal of Health Economics, 31(2), 406–439. Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2019

Authors and Affiliations

  1. 1.Department of Applied Pharmacy, Faculty of PharmacyUniversity of Veterinary and Pharmaceutical Sciences BrnoBrnoCzech Republic

Personalised recommendations